Cystic brain metastasis from prostate cancer: A case report and literature review

Crety, Charles Marchand; Ettalhaoui, Leila; Vernat, S. Servagi

doi:10.1016/j.eucr.2020.101219

Cited by 5 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain metastasis from prostate cancer presenting as a cystic tumor as seen in our patient is also a rarity. As per one case report only about 12 cases have been reported previously [3] . Several reports have shown that small cell histologic type has high rates of metastasis to the brain [ 4 , 5 ].…”

Section: Discussionmentioning

confidence: 93%

“…Most common histologic subtype of prostate cancer is adenocarcinoma accounting for about 99% of cases. It is interesting to note that despite adenocarcinoma being the most common type of prostate cancer, it is not the most common histologic type of prostate cancer to metastasize to the brain [2] , [3] , [4] . Brain metastasis from prostate cancer presenting as a cystic tumor as seen in our patient is also a rarity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic adenocarcinoma of the prostate presenting as a solitary cystic brain mass

Bandaru¹,

Adhikari²,

Ribeiro³

et al. 2022

Radiology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Metastatic adenocarcinoma of the prostate presenting as a solitary cystic brain mass

Bandaru¹,

Adhikari²,

Ribeiro³

et al. 2022

Radiology Case Reports

View full text Add to dashboard Cite

“…We found that despite being devoted to PCa, BMs is rare and uncommon [ 9 , 10 , 13 , 27 , 112 , 114 – 116 ], and the main survival rate estimations suggest that BMs in PCa has a poor prognosis [ 10 , 112 , 116 , 117 ]. As presented in Table 3 , many studies have been conducted to measure the survival rate and the mortality rate of PCa with BMs, for instance, it is reported in one study that the mean survival rate for only BMs in PCa is less than 28 months [ 9 , 10 , 13 – 24 , 26 – 30 , 32 , 36 – 74 , 117 ].…”

Section: Discussionmentioning

confidence: 99%

“…Our fndings suggest that radiotherapy is currently used as a common treatment in most patients with BMs [9,14,17,18,21,27,29,30,36,37,43,44,47,51,55,58,60,61,63,67,71,111]. In this regard, a study by Sita et al focusing on radiotherapy in BMs following PCa provides a signifcant breakthrough for radiotherapyprioritized treatment patterns.…”

Section: Treatments Of Bms In Pcamentioning

confidence: 92%

“…Recently, there has been a trend showing an increase in the number of PCa cases with a reported metastatic brain lesion. Tis brings to light the numerous challenges we face in terms of properly understanding, diagnosing, and managing PCa patients with BMs [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. Given the lack of knowledge regarding the issue of metastatic brain lesions in PCa, we decided to comprehensively and systematically review the latest evidence regarding the clinical manifestations, diagnosis, treatment, and prognosis of the BMs in PCa.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Aim. Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis. Methods. In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: (“Brain Neoplasms” OR “Central Nervous System Neoplasms”) and (“Prostatic Neoplasms” OR “Prostate”). Related studies were identified and reviewed. Results. A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs. Conclusion. We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.

show abstract

Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis

Mahmoud,

Childs,

Ahmed

et al. 2023

The Prostate

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) parenchymal brain metastases are uncommon and troubling observations in the course of the disease. Our study aims to evaluate the prevalence of brain metastases among PCa patients while reporting various therapeutic modalities, clinical features, and oncological outcomes.MethodsWe retrospectively identified 34 patients with parenchymal brain metastasis out of 4575 patients using a prospectively maintained database that contains clinicopathologic characteristics of PCa patients between January 2012 and December 2021. Based on the three treatment modalities used, the patients were divided into three groups: stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT), and systemic therapy alone. The Kaplan–Meier curve was used to calculate overall survival [OS] probability and the Cox proportional hazards regression model was used to compare between groups.ResultsAt the time of brain metastasis diagnosis, the median age was 66 years, the median (interquartile range [IQR]) prostate‐specific antigen (PSA) was 2.2 (0.1–26.6) ng/ml and the median (IQR) months from initial PCa diagnosis to brain metastasis development was 70.8 (27.6–100.9). The median (IQR) primary Gleason score was 8 (7–9) and over a median (IQR) follow‐up time of 2.2 (1.2–16.5) months, 76.5% (n = 26) of the patients died. Thirteen (38.2%) patients had solitary lesion, whereas 21 (61.8%) had ≥2 lesions. The lesions were supratentorial in 19 (55.9%) patients, infratentorial in six (17.6%), and both sides in nine (26.5%). Among all 34 patients, 10 (29.4%) were treated with SRS, seven (20.6%) with WBRT, and 17 (50%) with systemic therapy alone. OS varied greatly between the three treatment modalities (log‐rank test, p = 0.049). Those who were treated with SRS and WBRT had better OS compared with patients who were treated with systemic therapy alone (hazard ratio: 0.37, 95% confidence interval: 0.16–0.86, p = 0.022).ConclusionsIn our single‐institutional study, we confirmed that PCa brain metastasis is associated with poor survival outcomes and more advanced metastatic disease. Furthermore, we found that SRS and WBRT for brain metastasis in patients with recurrent PCa appear to be associated with improved OS as compared with systemic therapy alone and are likely secondary to selection bias.

show abstract

Cystic brain metastasis from prostate cancer: A case report and literature review

Cited by 5 publications

References 4 publications

Metastatic adenocarcinoma of the prostate presenting as a solitary cystic brain mass

Metastatic adenocarcinoma of the prostate presenting as a solitary cystic brain mass

The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review

Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis

Contact Info

Product

Resources

About